AI model aims to predict lymphoma treatment success
NCT ID NCT07409168
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will develop an artificial intelligence model to predict how well patients with a rare type of lymphoma (NK/T-cell) respond to their first chemotherapy. Researchers will collect medical images and tissue samples from 100 participants to train the AI. The goal is to help doctors personalize treatment more effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NATURAL KILLER/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug duo shows promise for rare blood cancer
- New combo therapy aims to tame rare lymphoma without heavy side effects
- Supercharged donor cells take on lymphoma in early trial
- Experimental combo aims to boost stem cell transplant for rare blood cancers
- New drug cocktail aims to tackle tough lymphoma